BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 23, 2003
View Archived Issues
BioMarin Stops Development Of Neutralase In CABG Surgery
Officials at BioMarin Inc. believe themselves to be fortunate in determining fairly early that their lead product, Neutralase, probably won't make it to market. (BioWorld Today)
Read More
Pain Therapeutics Raises $49.7M In Follow-On; Neose Getting $23M
Read More
Controversy Smolders As To U.S. Regions Of Lyme Disease, Borrelia burgdorferi, Despite M.D. Practices
Read More
First-Round Financing Of $12.5M Puts Ambrx On Development Path
Read More
Genzyme Invests $37.7M In CAT As Companies Restructure Pact
Read More
Other News To Note
Read More